AR106505A1 - Tratamiento de la oligo-ovulación relacionada con esteatosis hepática - Google Patents
Tratamiento de la oligo-ovulación relacionada con esteatosis hepáticaInfo
- Publication number
- AR106505A1 AR106505A1 ARP160103272A ARP160103272A AR106505A1 AR 106505 A1 AR106505 A1 AR 106505A1 AR P160103272 A ARP160103272 A AR P160103272A AR P160103272 A ARP160103272 A AR P160103272A AR 106505 A1 AR106505 A1 AR 106505A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- spironolactone
- pioglitazone
- metformin
- pharmaceutical composition
- Prior art date
Links
- 206010002659 Anovulatory cycle Diseases 0.000 title 1
- 230000002440 hepatic effect Effects 0.000 title 1
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 8
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 4
- 229960003105 metformin Drugs 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 229960005095 pioglitazone Drugs 0.000 abstract 4
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 abstract 4
- 229960002256 spironolactone Drugs 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 210000001596 intra-abdominal fat Anatomy 0.000 abstract 2
- 210000004185 liver Anatomy 0.000 abstract 2
- 229940127234 oral contraceptive Drugs 0.000 abstract 2
- 239000003539 oral contraceptive agent Substances 0.000 abstract 2
- 239000003433 contraceptive agent Substances 0.000 abstract 1
- 230000002254 contraceptive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Método y a una composición para su uso en el tratamiento de una condición que se beneficia de la reducción de grasa hepática y/o visceral, como el síndrome de ovario poliquístico en chicas adolescentes o en mujeres en edad de procrear e implica el uso de espironolactona, pioglitazona y metformina. Reivindicación 1: Composición farmacéutica que comprende espironolactona, pioglitazona y metformina para su uso en el tratamiento de un estado que se beneficia de la reducción de la grasa hepática y/o visceral. Reivindicación 6: Composición farmacéutica según las reivindicaciones 1 a 5, en la que cada una de espironolactona, pioglitazona y metformina se administran secuencialmente en formas de administración individuales separadas. Reivindicación 33: Método según cualquiera de las reivindicaciones 19 a 32, en el que las chicas adolescentes o mujeres en edad de procrear usan un anticonceptivo oral o no oral. Reivindicación 34: Método según la reivindicación 33, en el que dicho anticonceptivo no oral es un anticonceptivo intrauterino. Reivindicación 36: Composición farmacéutica en la que dicha composición farmacéutica comprende entre 25 y 100 mg de espironolactona y/o entre 5 y 15 mg de pioglitazona y/o entre 500 y 1500 mg de metformina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1518979.8A GB201518979D0 (en) | 2015-10-27 | 2015-10-27 | Treatment of hepatic steatosis related oligo-ovulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106505A1 true AR106505A1 (es) | 2018-01-24 |
Family
ID=55130283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103272A AR106505A1 (es) | 2015-10-27 | 2016-10-27 | Tratamiento de la oligo-ovulación relacionada con esteatosis hepática |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20190060328A1 (es) |
| EP (2) | EP3368044B1 (es) |
| JP (2) | JP6999903B2 (es) |
| KR (1) | KR102608158B1 (es) |
| CN (2) | CN108778285A (es) |
| AR (1) | AR106505A1 (es) |
| AU (1) | AU2016344737C1 (es) |
| BR (1) | BR112018008496A2 (es) |
| CA (1) | CA3003076C (es) |
| DK (1) | DK3368044T3 (es) |
| ES (1) | ES2883282T3 (es) |
| GB (1) | GB201518979D0 (es) |
| HU (1) | HUE055778T2 (es) |
| IL (1) | IL258876B (es) |
| LT (1) | LT3368044T (es) |
| MA (2) | MA43106B1 (es) |
| MX (2) | MX384040B (es) |
| PL (1) | PL3368044T3 (es) |
| RS (1) | RS62764B1 (es) |
| RU (1) | RU2745606C2 (es) |
| SI (1) | SI3368044T1 (es) |
| TW (1) | TWI791420B (es) |
| UY (1) | UY36967A (es) |
| WO (1) | WO2017072243A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111936171A (zh) | 2017-12-19 | 2020-11-13 | 阿库斯股份有限公司 | Aav介导的治疗性抗体到内耳的递送 |
| KR20210045404A (ko) | 2018-08-02 | 2021-04-26 | 오스피탈 산트 호안 데 데우 | 다낭성 난소 증후군 치료에 유용한 활성 약학적 성분들의 삼중 조합의 즉시 방출 제제 |
| EP3842803A1 (en) * | 2019-12-23 | 2021-06-30 | Katholieke Universiteit Leuven | Cxcl14 in polycystic ovary syndrome |
| JP2023526047A (ja) | 2020-05-13 | 2023-06-20 | アコーオス インコーポレイテッド | Ｓｌｃ２６ａ４関連難聴を治療するための組成物及び方法 |
| PH12023551518A1 (en) | 2020-12-01 | 2024-05-13 | Akouos Inc | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
| CA3203373A1 (en) | 2020-12-29 | 2022-07-07 | Emmanuel John Simons | Compositions and methods for treating clrn1-associated hearing loss and/or vision loss |
| CN118679182A (zh) | 2022-02-02 | 2024-09-20 | 阿库斯股份有限公司 | 用于治疗前庭神经鞘瘤相关症状的抗vegf抗体构建体和相关方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478852C1 (en) * | 1993-09-15 | 2001-03-13 | Sankyo Co | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus |
| US6046222A (en) * | 1993-09-15 | 2000-04-04 | Warner-Lambert Company | Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
| AU2001239826B2 (en) * | 2000-02-23 | 2006-06-15 | Orentreich Foundation For The Advancement Of Science, Inc. | Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus |
| GB0106565D0 (en) * | 2001-03-16 | 2001-05-09 | Leuven K U Res & Dev | Growth hormone treatment |
| GB0108863D0 (en) * | 2001-04-10 | 2001-05-30 | Leuven K U Res & Dev | Combinational therapy |
| US7105489B2 (en) * | 2002-01-22 | 2006-09-12 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
| AU2003256988A1 (en) * | 2002-12-11 | 2004-06-30 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
| GB0702537D0 (en) | 2007-02-12 | 2007-03-21 | Leuven K U Res & Dev | Treatment for excessive adiposity |
| US10474539B1 (en) * | 2015-12-18 | 2019-11-12 | EMC IP Holding Company LLC | Browsing federated backups |
| KR20210045404A (ko) * | 2018-08-02 | 2021-04-26 | 오스피탈 산트 호안 데 데우 | 다낭성 난소 증후군 치료에 유용한 활성 약학적 성분들의 삼중 조합의 즉시 방출 제제 |
-
2015
- 2015-10-27 GB GBGB1518979.8A patent/GB201518979D0/en not_active Ceased
-
2016
- 2016-10-27 SI SI201631327T patent/SI3368044T1/sl unknown
- 2016-10-27 US US15/771,317 patent/US20190060328A1/en not_active Abandoned
- 2016-10-27 RS RS20211116A patent/RS62764B1/sr unknown
- 2016-10-27 CN CN201680076653.5A patent/CN108778285A/zh active Pending
- 2016-10-27 HU HUE16788501A patent/HUE055778T2/hu unknown
- 2016-10-27 MA MA43106A patent/MA43106B1/fr unknown
- 2016-10-27 WO PCT/EP2016/075953 patent/WO2017072243A1/en not_active Ceased
- 2016-10-27 AR ARP160103272A patent/AR106505A1/es unknown
- 2016-10-27 MX MX2018005252A patent/MX384040B/es unknown
- 2016-10-27 RU RU2018119146A patent/RU2745606C2/ru active
- 2016-10-27 DK DK16788501.1T patent/DK3368044T3/da active
- 2016-10-27 PL PL16788501T patent/PL3368044T3/pl unknown
- 2016-10-27 EP EP16788501.1A patent/EP3368044B1/en active Active
- 2016-10-27 CA CA3003076A patent/CA3003076C/en active Active
- 2016-10-27 ES ES16788501T patent/ES2883282T3/es active Active
- 2016-10-27 JP JP2018521981A patent/JP6999903B2/ja active Active
- 2016-10-27 TW TW105134878A patent/TWI791420B/zh active
- 2016-10-27 EP EP21165556.8A patent/EP3892281A3/en not_active Withdrawn
- 2016-10-27 UY UY0001036967A patent/UY36967A/es unknown
- 2016-10-27 CN CN202311150878.9A patent/CN117379440A/zh active Pending
- 2016-10-27 BR BR112018008496A patent/BR112018008496A2/pt not_active Application Discontinuation
- 2016-10-27 AU AU2016344737A patent/AU2016344737C1/en active Active
- 2016-10-27 KR KR1020187014890A patent/KR102608158B1/ko active Active
- 2016-10-27 LT LTEPPCT/EP2016/075953T patent/LT3368044T/lt unknown
- 2016-10-27 MA MA054412A patent/MA54412A/fr unknown
-
2018
- 2018-04-23 IL IL258876A patent/IL258876B/en unknown
- 2018-04-26 MX MX2021007976A patent/MX2021007976A/es unknown
-
2021
- 2021-10-21 JP JP2021172610A patent/JP2022009374A/ja active Pending
-
2023
- 2023-06-28 US US18/343,553 patent/US20240000804A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR106505A1 (es) | Tratamiento de la oligo-ovulación relacionada con esteatosis hepática | |
| SV2018005610A (es) | Derivados de oxopiridina sustituidos | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| CL2018000705A1 (es) | Método de cristalización y biodisponibilidad | |
| MX379193B (es) | Composiciones en solucion solida y su uso en inflamacion cronica. | |
| DOP2016000253A (es) | Nuevos compuestos | |
| BR112022000982A2 (pt) | Forma de dosagem veterinária mastigável macia | |
| MX2018012618A (es) | Composiciones farmaceuticas orales de mesalazina. | |
| MX391152B (es) | Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas. | |
| CR20150266A (es) | Formulaciones de liberación modificada para oprozomib | |
| UY36117A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas. | |
| CL2018001590A1 (es) | Composiciones farmacéuticas que comprenden algun derivado de fenilaminopirimidina. | |
| AR106559A1 (es) | Suspensión acuosa para administración oral y método para su preparación | |
| PE20150721A1 (es) | Composicion farmaceutica que comprende gemigliptina y metformina, y metodo para su preparacion | |
| AR104185A1 (es) | Formulaciones farmacéuticas | |
| EP3599892A4 (en) | CHEWING GEL PRODUCTS FOR ACTIVE PHARMACEUTICAL SUBSTANCES | |
| UY37671A (es) | N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso | |
| CO2018004665A2 (es) | Compuestos oxadiazoespíricos | |
| CL2019003288A1 (es) | Una combinación farmacéutica para el tratamiento de un cáncer. | |
| BR112018071363A2 (pt) | composições farmacêuticas orais de nicotinamida | |
| MX2018006026A (es) | Un ligante de receptor de adenosina a3 para uso en el tratamiento de la acumulacion de grasa ectopica. | |
| MX389461B (es) | Composiciones que comprenden una matriz de polisacarido para la liberacion controlada de ingredientes activos | |
| CL2019003801A1 (es) | Nuevas formulaciones orales de belinostato. | |
| AR110374A1 (es) | Formas de dosificación de liberación modificada gastroretentivas para oprozomib y proceso para su fabricación |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |